Geminor M2 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The prolonged-release formulation ensures a sustained therapeutic effect, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Geminor M2 Forte is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy with either glimepiride or metformin. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular conditions. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea or diarrhea, and rarely, lactic acidosis. This medication should be used under medical supervision with appropriate lifestyle modifications to achieve optimal glycemic control and reduce the risk of diabetes-related complications.